Latest news and press releases about Ocugen, Inc. (OCGN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigme...
Price
| Price | $1.00 |
| Market Cap | $339M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -20.88 |
| EV / EBITDA | -6.40 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 1688.22% |
| Return on Invested Capital | -92.68% |
| Return on Assets | -65.87% |
| Gross Margin | 100.00% |
| Operating Margin | -1504.43% |
| Net Margin | -1786.27% |
Related companies: ADCT · ALMS · CMPX · FULC · LCTX · LXRX · NGNE
Explore sector: Healthcare · Biotechnology
More sections of OCGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks